Loading...
•
Jun 30
Aura Biosciences Q2 2025 Earnings Report
Aura Biosciences reported a larger net loss in Q2 2025 due to increased R&D investment, while maintaining a strong cash position after a recent equity raise.
Key Takeaways
Aura Biosciences continued advancing its clinical pipeline in Q2 2025, particularly in ocular and urologic oncology. The company increased R&D spending to support Phase 3 and Phase 1b/2 trials, resulting in a wider net loss, but remained well-capitalized through 2027.
Net loss widened to $27.0 million due to higher R&D expenses.
R&D costs rose to $22.9 million to support Phase 3 and bladder cancer trials.
Cash, cash equivalents, and marketable securities totaled $177.3 million as of June 30, 2025.
Company completed $75 million equity financing to fund operations into 1H 2027.
Aura Biosciences
Aura Biosciences
Forward Guidance
Aura expects to deliver data from multiple clinical trials across ocular and urologic oncology while maintaining sufficient capital to fund operations into 1H 2027.
Positive Outlook
- Ongoing global enrollment in Phase 3 CoMpass trial for early choroidal melanoma.
- Phase 1b/2 bladder cancer trial remains on track with two treatment strategies.
- Initial data from Phase 2 choroid metastases trial expected in 2025.
- Patent filed for new bladder formulation extending protection to 2046.
- Cash runway secured through early 2027 following $75M financing.
Challenges Ahead
- Net loss increased significantly year-over-year.
- R&D expenses continue to grow with expanding pipeline.
- Unrealized losses on marketable securities affected comprehensive results.
- Interest income declined year-over-year.
- No revenue generated from product sales.